To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection
Safety by reporting incidence and severity of Adverse events (graded as per CTCAE V5.0) of adverse events (AEs) and serious adverse events (SAEs),
To safety and tolerability of HRS-6209 in combination with fulvestrant in patients with advanced unresectable or metastatic breast cancer
Time frame: Screening up to study completion,, an average of 1 year.
Concentration
Plasma concentrations of HRS-6209 during multiple dosing, directly observed from data.
Time frame: From administration to C2, up to 4 months.
Cmax,ss
Css, max are steady-state maximum concentrations of HRS-6209 during multiple dosing, and are directly observed from data.
Time frame: From administration to C2, up to 4 months.
Cmin,ss
Css, min are the steady-state trough concentrations of HRS-6209 during multiple dosing, and are directly observed from data.
Time frame: From administration to C2, up to 4 months.
Objective Response Rate (ORR)
ORR refers to the proportion of subjects with a complete response (CR) or partial response (PR) based on all soft tissue assessments recorded from the date of first drug administration to either the date of radiographic disease progression (including bone progression and soft tissue progression), death from any cause, or the initiation of a new antitumor therapy, whichever occurs first. For subjects with CR or PR at the first evaluation, the efficacy should be confirmed 4 weeks later or at the next tumor imaging evaluation. The numerator includes subjects with a confirmed CR/PR at least 4 weeks after the initial assessment. The denominator consists of subjects with measurable target lesions at baseline.
Time frame: Screening up to study completion, an average of 2 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Best of Response (DoR)
BOR refers to the best response of tumor evaluation, including CR, PR, stable disease (SD), progressive disease (PD), and not evaluable for response (NE).
Time frame: Screening up to study completion, an average of 2 years.
Disease Control Rate (DCR)
DCR refers to the time from the first occurrence of CR or PR to PD or death from any cause, whichever occurs first, in subjects with objective response. DCR will be recorded from baseline visit until the end of the study.
Time frame: Screening up to study completion, an average of 2 years.
rPFS (radiographic progression-free survival
rPFS refers to the time from the first dose of investigational drug to the first radiographic PD or death from any cause (whichever occurs first) as assessed by the investigator. rPFS will be recorded from baseline visit until the end of the study.
Time frame: Screening up to study completion, an average of 2 years.